Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis seeks FDA approval to develop cancer compound
XL184 is the seventh drug to reach clinical development from the company’s internal discovery program within two years. Pending FDA clearance, Exelixis intends to initiate a phase I
XL184 is the seventh drug to reach clinical development from the company’s internal discovery program within two years. Pending FDA clearance, Exelixis intends to initiate a phase I
Original data analyzed by two cardiologists threw up safety concerns around the drug suggesting it may damage the kidneys and even increase the risk of death. The following
The trial results showed that immediate-release Zegerid (omeprazole) powder for oral suspension 40mg to be more effective than Protonix (pantoprazole) delayed-release tablets 40mg when dosed once a day
The data reported at the American Diabetes Association (ADA) Annual Meeting in San Diego suggests that ruboxistaurin mesylate was effective in persons with type 2 diabetes and kidney
The revelation from the highly respected cancer investigation body has been made at the 9th International Conference on Malignant Lymphoma and comes in the wake of a study
Results from the VYVA (VYtorin Versus Atorvastatin) trial involving a subgroup of 428 patients with type 2 diabetes were evaluated. In the new analysis, results showed that Vytorin
The positive results were presented by principal investigator, Dr Barbara Pro, at the International Conference on Malignant Lymphoma in Lugano, Switzerland, following trials carried out at the M.D.
Silodosin is a novel alpha(1)-adrenoceptor antagonist with high uroselectivity. The company licensed silodosin from Kissei Pharmaceuticals Co., of Japan in April 2004, to develop and market silodosin in
The efficacy of Lyrica was established in three double-blind, controlled trials involving 1,052 patients. At the start of treatment with Lyrica, patients experienced approximately ten seizures a month
The database is being developed in an attempt to enhance Pfizer’s overall consumer outreach efforts. Pfizer hopes to utilize Epsilon’s capabilities to gain a broader range of business